Lane Labs
This article was originally published in The Rose Sheet
Executive Summary
Dietary supplement firm has discontinued manufacturing skin cream SkinAnswer and two nutritional supplements, Benefin and MGN-3, the company announces, after a permanent injunction was issued July 13 barring the firm from selling the products unless approved by FDA. "We are very disappointed and will pursue an appeal," the company says in a statement. Lane Labs argues the products represent a breakthrough in the natural health industry, but court rules that the items, marketed as cancer therapies, are unapproved new drugs (1"The Rose Sheet" July 19, 2004, p. 7)...
You may also be interested in...
Lane Labs Must Discontinue SkinAnswer Cancer Claims Under Injunction
The seven-year struggle between federal regulators and dietary supplement marketer Lane Labs-USA has formally concluded with a permanent injunction issued in Newark, N.J. federal court July 13
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.